Related Experiment Video

Updated: May 29, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Primary cardiac angiosarcoma with good response to Paclitaxel

M P Ram Prabu, Sanjay Thulkar, Ruma Ray

    Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
    |September 16, 2011
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: May 29, 2026

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Burden of sudden death in young adults: A one-year observational study at a tertiary care centre in India.

    The Indian journal of medical research·2025

    Sudden cardiac death in young: A cardiac-focused autopsy and molecular study to identify the cause.

    Indian heart journal·2025

    Abatacept: A Promising Repurposed Solution for Myocardial Infarction-Induced Inflammation in Rat Models.

    Oxidative medicine and cellular longevity·2024

    Arglabin: A mediator of inflammasome modulated and independent myocardial injury (PARA-AMI study).

    European journal of pharmacology·2024

    Exchange bias and magnetic memory effect in hole doped Nd0.78Sr0.22CoO3 nanoparticles.

    RSC advances·2022

    An Untargeted LC-MS based approach for identification of altered metabolites in blood plasma of rheumatic heart disease patients.

    Scientific reports·2022

    Clinical Responses to Tarlatamab Among Patients with Pulmonary Carcinoid.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Comprehensive Patient Reported Outcomes (PROs) from NRG Oncology/Alliance LU005: A Randomized Trial Of Chemoradiation +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Disease Kinetics and Practice Patterns in ≥4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

    Impact of Genomic Subtype on Intracranial Outcomes in Treatment-naive EGFR mutant NSCLC with Osimertinib (IGnITE).

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us